Absci Corporation (NASDAQ: ABSI) a data-first generative AI drug
creation company, and Twist Bioscience Corporation (NASDAQ: TWST) a
company enabling customers to succeed through its offering of
high-quality synthetic DNA using its silicon platform, today
unveiled a collaboration to design a novel therapeutic using
generative AI.
“Bringing together two leaders in biotechnology innovation
represents an opportunity to accelerate pharmaceutical R&D,”
said Absci Founder & CEO Sean McClain. “We are excited to
strengthen our relationship with Twist and leverage the power of
our shared platforms to bring better biologics to patients
faster.”
Through this new collaboration, Absci and Twist will design a
novel therapeutic candidate against an undisclosed target using
Absci’s advanced generative AI platform and Twist’s synthetic DNA
platform. The program will leverage Absci’s AI de novo design
capabilities and Twist’s silicon-based synthesis platform,
including its Multiplexed Gene Fragments for the testing and
validation of antibody candidates designed using Absci’s generative
AI technology platform. Twist and Absci intend to seek a partner
for human clinical development and commercialization.
“We have been working with Absci for several years and look
forward to extending our collaboration beyond a preferred supplier
to leverage their AI platform along with Twist’s capabilities to
discover antibodies to a key biological target that potentially
impacts multiple disease areas,” said Emily M. Leproust, Ph.D., CEO
and cofounder of Twist Bioscience.
This program adds to Absci’s growing portfolio of collaboration
programs with industry-leading pharmaceutical companies such as
AstraZeneca and Merck, as well as with leading academic institutes
such as Memorial Sloan Kettering Cancer Center. In addition to its
partnered programs, Absci continues to advance an internal pipeline
of multiple drug candidates.
For this program, Twist will apply products from its SynBio
portfolio developed for antibody discovery including Multiplexed
Gene Fragments, Express portfolio and synthesis of long DNA. This
partnership illustrates the value of Twist’s platform from
individual pieces of DNA all the way through antibody
discovery.
About AbsciAbsci is a data-first generative AI
drug creation company that combines AI with scalable wet lab
technologies to create better biologics for patients, faster. Our
Integrated Drug Creation™ platform unlocks the potential to
accelerate time to clinic and increase the probability of success
by simultaneously optimizing multiple drug characteristics
important to both development and therapeutic benefit. With the
data to train, the AI to create, and the wet lab to validate, we
can screen billions of cells per week, allowing us to go from
AI-designed antibodies to wet lab-validated candidates in as little
as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI
Research Lab in New York City and an Innovation Center in Zug,
Switzerland. Visit www.absci.com and follow us on LinkedIn
(@absci), X (Twitter) (@Abscibio), and YouTube.
About Twist Bioscience CorporationTwist
Bioscience is a leading and rapidly growing synthetic biology and
genomics company that has developed a disruptive DNA synthesis
platform to industrialize the engineering of biology. The core of
the platform is a proprietary technology that pioneers a new method
of manufacturing synthetic DNA by “writing” DNA on a silicon chip.
Twist is leveraging its unique technology to manufacture a broad
range of synthetic DNA-based products, including synthetic genes,
tools for next-generation sequencing (NGS) preparation, and
antibody libraries for drug discovery and development. Twist is
also pursuing longer-term opportunities in digital data storage in
DNA and biologics drug discovery. Twist makes products for use
across many industries including healthcare, industrial chemicals,
agriculture and academic research. Follow us on LinkedIn |
X | YouTube | Instagram
Absci Forward-Looking StatementsCertain
statements in this press release that are not historical facts are
considered forward-looking within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, including statements
containing the words “will,” “may,” “pursues,” “anticipates,”
“plans,” “believes,” “aims,” “potential,” “forecast,” “estimates,”
“extends,” “expects,” and “intends,” or similar expressions. We
intend these forward-looking statements, including statements
regarding the capabilities of our Integrated Drug Creation
platform, our technology development efforts and the application of
those efforts, the potential benefits of our partnership with
Twist, the plans and success of our current and future partnerships
and the ability to generate advancements towards treating disease
using generative AI drug creation to accelerate the development of
novel candidate therapies, the anticipated value to us under our
partnerships, and our internal therapeutic asset programs, to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Securities Exchange Act, and we make this
statement for purposes of complying with those safe harbor
provisions. These forward-looking statements reflect our current
views about our plans, intentions, expectations, strategies, and
prospects, which are based on the information currently available
to us and on assumptions we have made. We can give no assurance
that the plans, intentions, expectations, or strategies will be
attained or achieved, and furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control, including, without limitation, risks and
uncertainties relating to our ability to effectively collaborate on
research, drug discovery and development activities with our
partners or potential partners, our dependence on third parties to
support our internal development programs, including for the
manufacture and supply of preclinical and clinical supplies of our
product candidates or components thereof, our existing and
potential partners’ ability and willingness to pursue the
development and commercialization of programs or product candidates
under the terms of our partnership agreements, and overall market
conditions and regulatory developments that may affect our and our
partners’ activities under these agreements, along with those risks
set forth in our most recent periodic report filed with the U.S.
Securities and Exchange Commission, as well as discussions of
potential risks, uncertainties, and other important factors in our
subsequent filings with the U.S. Securities and Exchange
Commission. Except as required by law, we assume no obligation to
update publicly any forward-looking statements, whether as a result
of new information, future events, or otherwise.
Twist Bioscience Legal Notice Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements. All statements other than statements of historical
facts contained herein are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including statements regarding the potential
benefits of our partnership with Absci and the success of our
partnership and the ability to generate advancements towards
treating disease using generative AI drug creation to accelerate
the development of novel candidate therapies. Forward-looking
statements involve known and unknown risks, uncertainties, and
other important factors that may cause Twist Bioscience’s actual
results, performance, or achievements to be materially different
from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the ability to achieve the
expected benefits of Twist Bioscience’s restructuring activities
and reduced investments in DNA data storage; the ability to attract
new customers and retain and grow sales from existing customers;
the ability of Twist Bioscience to achieve sufficient revenue to
achieve or maintain positive cash flow from operations or
profitability in any given period will depend heavily on the
success of our existing products and the development and
commercialization of additional products in the synthetic biology,
biologic drug and data storage industries; risks and uncertainties
of rapidly changing technologies and extensive competition in
synthetic biology that could make the products Twist Bioscience is
developing obsolete or non-competitive; uncertainties of the
retention of significant customers; the ability of Twist Bioscience
to successfully integrate acquired companies and to achieve
expected benefits from acquisitions; supply chain and other
disruptions; risks of third party claims alleging infringement of
patents and proprietary rights or seeking to invalidate Twist
Bioscience’s patents or proprietary rights; and the risk that Twist
Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Annual Report on Form 10-K
filed with the SEC on November 21, 2023 and subsequent filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Twist Bioscience
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Absci Investor ContactAlex KhanVP, Finance
& Investor Relationsinvestors@absci.com
Absci Media Contactpress@absci.com
Twist Investor Contact:Angela BittingSVP,
Corporate Affairs925-202-6211abitting@twistbioscience.com
Twist Media Contact:Amanda
HoulihanCommunications
Manager774-265-5334ahoulihan@twistbioscience.com
AbSci (NASDAQ:ABSI)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
AbSci (NASDAQ:ABSI)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024